|Bid||0.00 x 1300|
|Ask||0.00 x 800|
|Day's range||157.78 - 162.14|
|52-week range||123.57 - 164.13|
|Beta (5Y monthly)||0.88|
|PE ratio (TTM)||131.64|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
The drive to cure deadly diseases is about to enter a new and demanding phase as the pharmaceutical industry prepares for the first time to test the appetite for hyper-expensive gene therapies in Europe. The willingness of traditionally cash-strapped European health systems to pay for these innovative treatments will affect future investment in the field. , a treatment for rare blood disorder Beta thalassaemia that is manufactured by Bluebird Bio.
Solid technological suite, growth opportunities from emerging markets and efforts to boost its presence in real-world business are the major positives for IQVIA Holdings (IQV).
When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
IQVIA (IQV) delivered earnings and revenue surprises of 1.91% and 0.16%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IQVIA's (IQV) latest launch is aimed at helping MedTech companies comply with the new European Union Medical Device Regulation, through extended capabilities.
IQVIA Holdings (IQV) is likely to benefit from the evolving growth opportunities in the life sciences industry. A highly leveraged balance sheet remains a concern.
In the high-risk world of biotech investing, there are no guarantees of success. Still, sometimes investors can find places where the odds look reasonable enough to consider buying shares.
IQVIA (IQV) delivered earnings and revenue surprises of 2.68% and 1.74%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?